Apoptotic cell death in toxic epidermal necrolysis: the Fas ligand assumption.
Gravante
G
G
Esposito
G
G
Filingeri
V
V
Delogu
D
D
Castrì
F
F
Montone
A
A
D017209:Apoptosis / Q000276:immunology / Q000502:physiology*; D015415:Biomarkers / Q000032:analysis; D053222:Fas Ligand Protein; D006801:Humans; D020287:In Situ Nick-End Labeling; D008562:Membrane Glycoproteins / Q000032:analysis / Q000276:immunology / Q000502:physiology*; D015203:Reproducibility of Results; D018401:Sample Size; D012867:Skin / Q000737:chemistry / Q000276:immunology / Q000473:pathology / Q000503:physiopathology; D013262:Stevens-Johnson Syndrome / Q000276:immunology / Q000473:pathology / Q000503:physiopathology*; D048069:Tumor Necrosis Factors / Q000032:analysis / Q000276:immunology / Q000502:physiology*; D019014:fas Receptor / Q000032:analysis
D015415:Biomarkers; C505661:FASLG protein, human; D053222:Fas Ligand Protein; D008562:Membrane Glycoproteins; D048069:Tumor Necrosis Factors; D019014:fas Receptor